RedHill Biopharma (RDHL) Interest & Investment Income (2012 - 2023)

RedHill Biopharma (RDHL) has reported Interest & Investment Income for 12 consecutive years, with $7.1 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Interest & Investment Income rose 326.9% year-over-year to $7.1 million in Q2 2023; TTM through Jun 2023 was $40.6 million, a 2284.89% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, down 84.21% from the prior year.
• Interest & Investment Income was $7.1 million for Q2 2023 at RedHill Biopharma, down from $21.6 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $21.6 million in Q1 2023 and troughed at -$214000.0 in Q1 2020.
• A 5-year average of $2.5 million and a median of $139000.0 in 2019 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income tumbled 157.22% in 2020 and surged 215720.0% in 2023, its largest moves.
• Over 5 years, Interest & Investment Income stood at $260000.0 in 2019, then plunged by 92.31% to $20000.0 in 2020, then sank by 40.0% to $12000.0 in 2021, then surged by 72400.0% to $8.7 million in 2022, then declined by 18.45% to $7.1 million in 2023.
• The last three Interest & Investment Income figures came in at $7.1 million (Q2 2023), $21.6 million (Q1 2023), and $8.7 million (Q4 2022), per Business Quant data.